【摘要】 目的评价恩度(重组人血管内皮抑素,endostar,YH-16)联合GP(吉西他滨+顺铂)治疗老年性晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法 72例老年性晚期NSCLC患者被随机分为两组,试验组(40例)应用YH-16联合GP方案,对照组(32例)予以常规GP方案化疗。两组患者均至少完成2个周期。结果试验组有效率(RR)为42.5%,临床获益率(CBR)为80.0%;对照组有效率(RR)28.13%,临床获益率(CBR)为56.2%。两组毒副反应相似,患者的主要毒副反应有恶心、呕吐、白细胞减少等。结论恩度联合GP方案治疗老年性晚期NSCLC是一种有效、安全的方案。更多还原

【Abstract】 Objective To evaluate the efficacy and security of endostar injection combined with GP regimen for the treatment of elderly advanced non-small cell lung cancer(NSCLC).Methods Seventy-two elderly patients with advanced non-small cell lung cancer were randomly divided into two groups.40 patients served as trial group were treated with the combination of YH-16 with GP regimen,while 32 patients as control group only received GP regimen.At least after two cycles,the efficacy and toxicity were evaluated in all patients.Results The efficiency rates of trial group and control group were 42.5% and 28.13%,respectively.The clinical benefit rates in trial group and control group were 80.0% and 56.2%,respectively.The side-effects were similar in the two groups,including nausea,vomiting and neutropenia.Conclusions YH-16 combined with GP is an effective and safe therapy for elderly advanced NSCLC.更多还原